Patent intelligence · US
US 12377082
Nicorandil derivatives
Nicorandil derivatives
Patent details — US 12377082
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 5, 2025
- Expiration
- Jul 31, 2045
- Applicant
- UNICYCIVE THERAPEUTICS, INC.
- Claims
- 14
- CPC classes
- A61K, A61K31/4425, A61K31/4545, A61K31/455
Quick answer
US 12377082 (Nicorandil derivatives) is held by UNICYCIVE THERAPEUTICS, INC.. Status: granted. Granted Aug 5, 2025. Expires Jul 31, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- UNICYCIVE THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K31/4425, A61K31/4545, A61K31/455, A61P, A61P13/12
More from UNICYCIVE THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12377082?
US 12377082 (Nicorandil derivatives) is held by UNICYCIVE THERAPEUTICS, INC.. Status: granted. Granted Aug 5, 2025. Expires Jul 31, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12377082?
UNICYCIVE THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 12377082 expire?
Our index shows an expiration date of Jul 31, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.